Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia

Diego J. Maselli, Juan F. Fernandez, Christine Y. Whong, Kelly Echevarria, Anoop M Nambiar, Antonio R Anzueto, Marcos Restrepo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Ceftaroline fosamil (ceftaroline) was recently approved for the treatment of community- acquired pneumonia (CAP) and complicated skin infections. This newly developed cephalosporin possesses a broad spectrum of activity against gram-positive and gramnegative bacteria. Most importantly, ceftaroline demonstrates potent in vitro antimicrobial activity against multi-drug resistant Streptococcus pneumoniae and methicillin-resistant strains of Staphylococcus aureus. In two Phase III, double-blinded, randomized, prospective trials (FOCUS 1 and FOCUS 2), ceftaroline was shown to be non-inferior to ceftriaxone for the treatment of CAP in hospitalized patients. Ceftaroline exhibits low resistance rates and a safety profile similar to that of other cephalosporins. In this review, we will evaluate the pharmacological characteristics, safety, antimicrobial properties, and efficacy of ceftaroline and its applications in the treatment of CAP.

Original languageEnglish (US)
Pages (from-to)43-51
Number of pages9
JournalInfection and Drug Resistance
Volume5
Issue number1
StatePublished - 2012

Fingerprint

Bacterial Pneumonia
Pneumonia
Cephalosporins
Safety
Ceftriaxone
Gram-Positive Bacteria
Methicillin-Resistant Staphylococcus aureus
Streptococcus pneumoniae
Therapeutics
T 91825
Pharmacology
Skin
Infection
Pharmaceutical Preparations

Keywords

  • Ceftaroline
  • Cephalosporins
  • Community acquired pneumonia
  • Pneumonia
  • S. aureus
  • S. pneumoniae

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology

Cite this

Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. / Maselli, Diego J.; Fernandez, Juan F.; Whong, Christine Y.; Echevarria, Kelly; Nambiar, Anoop M; Anzueto, Antonio R; Restrepo, Marcos.

In: Infection and Drug Resistance, Vol. 5, No. 1, 2012, p. 43-51.

Research output: Contribution to journalArticle

Maselli, Diego J. ; Fernandez, Juan F. ; Whong, Christine Y. ; Echevarria, Kelly ; Nambiar, Anoop M ; Anzueto, Antonio R ; Restrepo, Marcos. / Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. In: Infection and Drug Resistance. 2012 ; Vol. 5, No. 1. pp. 43-51.
@article{b092f72d39584b2e8b7c27b78a37b737,
title = "Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia",
abstract = "Ceftaroline fosamil (ceftaroline) was recently approved for the treatment of community- acquired pneumonia (CAP) and complicated skin infections. This newly developed cephalosporin possesses a broad spectrum of activity against gram-positive and gramnegative bacteria. Most importantly, ceftaroline demonstrates potent in vitro antimicrobial activity against multi-drug resistant Streptococcus pneumoniae and methicillin-resistant strains of Staphylococcus aureus. In two Phase III, double-blinded, randomized, prospective trials (FOCUS 1 and FOCUS 2), ceftaroline was shown to be non-inferior to ceftriaxone for the treatment of CAP in hospitalized patients. Ceftaroline exhibits low resistance rates and a safety profile similar to that of other cephalosporins. In this review, we will evaluate the pharmacological characteristics, safety, antimicrobial properties, and efficacy of ceftaroline and its applications in the treatment of CAP.",
keywords = "Ceftaroline, Cephalosporins, Community acquired pneumonia, Pneumonia, S. aureus, S. pneumoniae",
author = "Maselli, {Diego J.} and Fernandez, {Juan F.} and Whong, {Christine Y.} and Kelly Echevarria and Nambiar, {Anoop M} and Anzueto, {Antonio R} and Marcos Restrepo",
year = "2012",
language = "English (US)",
volume = "5",
pages = "43--51",
journal = "Infection and Drug Resistance",
issn = "1178-6973",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia

AU - Maselli, Diego J.

AU - Fernandez, Juan F.

AU - Whong, Christine Y.

AU - Echevarria, Kelly

AU - Nambiar, Anoop M

AU - Anzueto, Antonio R

AU - Restrepo, Marcos

PY - 2012

Y1 - 2012

N2 - Ceftaroline fosamil (ceftaroline) was recently approved for the treatment of community- acquired pneumonia (CAP) and complicated skin infections. This newly developed cephalosporin possesses a broad spectrum of activity against gram-positive and gramnegative bacteria. Most importantly, ceftaroline demonstrates potent in vitro antimicrobial activity against multi-drug resistant Streptococcus pneumoniae and methicillin-resistant strains of Staphylococcus aureus. In two Phase III, double-blinded, randomized, prospective trials (FOCUS 1 and FOCUS 2), ceftaroline was shown to be non-inferior to ceftriaxone for the treatment of CAP in hospitalized patients. Ceftaroline exhibits low resistance rates and a safety profile similar to that of other cephalosporins. In this review, we will evaluate the pharmacological characteristics, safety, antimicrobial properties, and efficacy of ceftaroline and its applications in the treatment of CAP.

AB - Ceftaroline fosamil (ceftaroline) was recently approved for the treatment of community- acquired pneumonia (CAP) and complicated skin infections. This newly developed cephalosporin possesses a broad spectrum of activity against gram-positive and gramnegative bacteria. Most importantly, ceftaroline demonstrates potent in vitro antimicrobial activity against multi-drug resistant Streptococcus pneumoniae and methicillin-resistant strains of Staphylococcus aureus. In two Phase III, double-blinded, randomized, prospective trials (FOCUS 1 and FOCUS 2), ceftaroline was shown to be non-inferior to ceftriaxone for the treatment of CAP in hospitalized patients. Ceftaroline exhibits low resistance rates and a safety profile similar to that of other cephalosporins. In this review, we will evaluate the pharmacological characteristics, safety, antimicrobial properties, and efficacy of ceftaroline and its applications in the treatment of CAP.

KW - Ceftaroline

KW - Cephalosporins

KW - Community acquired pneumonia

KW - Pneumonia

KW - S. aureus

KW - S. pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=84861374442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861374442&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 43

EP - 51

JO - Infection and Drug Resistance

JF - Infection and Drug Resistance

SN - 1178-6973

IS - 1

ER -